Stock search

Ticker or company name

Compare stocks

Market: US

  • BIIBBiogen
  • INCYIncyte
  • MRNAModerna

Add stock

Ticker or company

Summary

BIIB
Biogen
$251,65Down −0,69%
Year: Up +54%
31/100Ratio would not consider buying
Open stock page
INCY
Incyte
$120,27Down −0,58%
Year: Up +15%
44/100Best scoreRatio would watch
Open stock page
MRNA
Moderna
$215,27Down −3,63%
Year: Up +795%
22/100Ratio would not consider buying
Open stock page

Verdict

INCY has the best score (44). INCY grows revenue the fastest. INCY is the cheapest by forward P/E. INCY has the highest net margin. MRNA has 7 of 10 checks in the red zone.

Verdict by our methodology based on current metrics. Not an investment recommendation.

Traffic light — 10 checks

CheckBIIB1 ✓ 3 — 4 ✕INCY3 ✓ 2 — 4 ✕MRNA2 ✓ 0 — 7 ✕
P/E vs its history107,861,1—
P/E vs industry107,861,1—
Forward P/E16,515,5n/a—
Revenue growth, YoY+2,3%+24,9%+13,1%
EPS growth, YoY−78,9%−68,1%—
Net margin3,4%6,7%−110,5%
Net debt / EBITDAn/a—−4,5—
Free cash flow$2,07 bn$745 m−$1,97 bn
Share count over a year+0,5%+0,9%+10,3%
Cash runwayn/anot neededn/anot needed0,8 yrs

Metrics

Best WorstNo mark — in between

Metric · betterBIIBTTMINCYTTMMRNATTMIndustry medianTTM
P/E TTM ↓Worst: 107,8Best: 61,1n/a42,1
Forward P/E ↓Worst: 16,5Best: 15,5n/a18,7
PEG ↓Worst: 22,4Best: 4,2n/a4,1
P/S TTM ↓Best: 3,64,1Worst: 35,86,6
EV/EBITDA ↓36,2Best: 32,7Worst: 105,928,2
P/FCF ↓22,1Best: 12,8Worst: 101,426,0

Price, %

  • BIIBn/a
  • INCYn/a
  • MRNAn/a

Returns

Best WorstNo mark — in between

PeriodBIIBINCYMRNA
1 yearn/an/an/a
3 yearsn/an/an/a
5 yearsn/an/an/a
All timen/an/an/a

“Per year” is the average annual return: 90% growth over 3 years is 23,9% per year, not 30%. “All time” starts at the IPO, so only “per year” compares fairly. Prices adjusted for splits, dividends reinvested.

Analysts and insiders

Best WorstNo mark — in between

BIIBINCYMRNA
Share of “buy”Best: 73%54%Worst: 32%
Beat the forecastBest: 4 of 4Worst: 3 of 4Best: 4 of 4
Average “surprise”+24,0%Worst: +18,4%Best: +43,7%
Insiders over 12 monthssales $904 829sales $65,8 msales $78,9 m

Details are on each stock page.